The panic disorders market size has grown steadily in recent years. It will grow from $10.73 billion in 2024 to $11.19 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to antidepressant medications, increased mental health awareness, increased stress levels, access to mental health services, advancements in diagnostic criteria.
The panic disorders market size is expected to see strong growth in the next few years. It will grow to $13.96 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to emerging pharmacological treatments, telepsychiatry services, focus on comorbidities, global mental health initiatives, pharmacogenomics in treatment, public education programs. Major trends in the forecast period include digital mental health interventions, telemedicine for panic disorder treatment, innovations in medications, neurobiological research, remote monitoring and wearable technology.
An upsurge in the population of psychiatric patients is poised to propel the expansion of the panic disorder market in the foreseeable future. Psychiatric patients, affected by mental health conditions that disrupt various aspects of their cognitive, emotional, and social functioning, are susceptible to panic disorder, characterized by sudden and intense episodes of anxiety. Treatment for individuals dealing with psychiatric conditions often involves a multifaceted approach combining therapy, medication, and lifestyle modifications to alleviate panic attack symptoms, enhance overall well-being, and foster effective coping mechanisms. For instance, the State of Mental Health in America 2022 report by Mental Health America noted an increase in psychiatric patients, reaching 49,564,000 individuals, constituting 19.86% of the total US population in 2022, compared to 47,132,000 individuals, comprising 19.00% of the total US population in 2021. Hence, the rise in psychiatric patient numbers is set to drive the growth of the panic disorder market.
The growing use of telehealth is expected to significantly boost the panic disorders market. Telehealth, which involves electronic communication methods like videoconferencing, phone calls, and secure messaging, enables remote consultations and healthcare services, including psychotherapy and counseling for individuals suffering from panic disorders. This technology makes it easier for patients to access mental health services without the need for in-person visits, improving accessibility and convenience. For example, a report from FAIR Health Inc. in April 2023 revealed a 7.3% increase in telehealth usage, rising from 5.5% in December 2022 to 5.9% of medical claim lines in January 2023. As telehealth continues to grow, its impact on the panic disorders market is expected to drive demand for effective treatment options and remote therapeutic services.
Key companies engaged in the panic disorder market are concentrating on the development of advanced medications, notably extended-release capsules, to fortify their foothold in the market. Extended-release capsules are medications designed to gradually release the active ingredients over an extended period, typically 12 or 24 hours, suitable for managing conditions requiring prolonged medication. As an example, in May 2023, Granules India Ltd., an Indian pharmaceutical company, obtained abbreviated new drug application (ANDA) approval from the US Food & Drug Administration (USFDA) for Venlafaxine hydrochloride extended-release capsules. These capsules have demonstrated bioequivalence with the reference-listed drug product (RLD), Effexor XR Extended-Release Capsules, manufactured by Upjohn US 2 LLC. Venlafaxine HCl extended-release capsules are prescribed to manage various conditions such as generalized anxiety disorder (GAD), major depressive disorder (MDD), panic disorder (PD), and social anxiety disorder (SAD). They operate by increasing serotonin and norepinephrine levels in the brain, usually starting at a dosage of 75 mg per day and adjusted as required under a doctor's supervision.
In February 2023, Vistagen Therapeutics Inc., a clinical-stage biopharmaceutical company based in the United States, successfully acquired Pherin Pharmaceuticals Inc. for an undisclosed sum. This strategic acquisition positions Vistagen to advance and bring to market innovative treatments designed for individuals dealing with depression and anxiety disorders. The collaboration is anticipated to enhance the commercial prospects of each drug candidate, strengthening Vistagen's portfolio in addressing mental health challenges. Pherin Pharmaceuticals Inc., the acquired company, specializes in drug development focused on panic disorders.
Major companies operating in the panic disorders market report are F. Hoffmann-La Roche Ltd., Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Baxter Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., H. Lundbeck A/S, Shionogi & Co Ltd., Recordati S.p.A, Neurocrine Biosciences Inc., Neuraxpharm, Actavis Plc., Noven Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., VistaGen Therapeutics, Valeant Pharmaceuticals International Inc., LIFECARE NEURO PRODUCTS LTD.
North America was the largest region in the panic disorders market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the panic disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the panic disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The panic disorder market consists of revenue earned by entities by providing services such as physical tests, cognitive behavioral therapy (CBT), and psychological evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The panic disorder market includes sales of tablets and injectables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Panic disorder is a specific type of anxiety condition characterized by unexpected and recurring episodes of intense anxiety accompanied by physical symptoms such as shortness of breath, chest pain, heart palpitations, nausea, and abdominal discomfort. Treatment for panic disorder typically involves a combination of medication and psychotherapy.
The main subtypes of panic disorders include agoraphobia, social anxiety disorder (SAD), obsessive-compulsive disorder (OCS), bipolar disorder, post-traumatic stress disorder (PTSD), and major depressive disorder. Agoraphobia involves the intentional avoidance of places or situations that may trigger panic symptoms, leading to feelings of confinement, helplessness, or social discomfort. Various treatment options include medication, beta-blockers, serotonin and norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, anti-epilepsy medications, and others, which can be administered orally, through injections, and other methods. These treatments are available through hospital pharmacies, retail pharmacies, and online pharmacy stores.
The panic disorders market research report is one of a series of new reports that provides panic disorders market statistics, including panic disorders industry global market size, regional shares, competitors with a panic disorders market share, detailed panic disorders market segments, market trends and opportunities, and any further data you may need to thrive in the panic disorders industry. This panic disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Panic Disorders Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on panic disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for panic disorders? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The panic disorders market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Agoraphobia; Social Anxiety Disorder (SAD); Obsessive-Compulsive Disorder (OCD); Bipolar Disorder; Post-Traumatic Stress Disorder (PTSD); Major Depressive Disorder2) By Treatment: Medication; Beta Blockers; Serotonin And Norepinephrine Reuptake Inhibitors (SNRIs); Benzodiazepines; Anti-Epilepsy; Other Treatments
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administrations
4) By End Use: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacy Stores
Subsegments:
1) By Agoraphobia: Situational Agoraphobia; Non-Situational Agoraphobia2) By Social Anxiety Disorder (SAD): Performance Anxiety; Generalized Social Anxiety
3) By Obsessive-Compulsive Disorder (OCD): Contamination OCD; Harm OCD; Checking OCD; Symmetry OCD
4) By Bipolar Disorder: Bipolar I Disorder; Bipolar II Disorder; Cyclothymic Disorder
5) By Post-Traumatic Stress Disorder (PTSD): Acute PTSD; Chronic PTSD; Complex PTSD
6) By Major Depressive Disorder: Recurrent Major Depressive Disorder; Single Episode Major Depressive Disorder
Key Companies Mentioned: F. Hoffmann-La Roche Ltd; Sanofi S.A; Bristol-Myers Squibb Company; AstraZeneca plc; Abbott Laboratories
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Panic Disorders market report include:- F. Hoffmann-La Roche Ltd
- Sanofi S.A
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Abbott Laboratories
- GlaxoSmithKline plc
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH.
- Baxter Inc
- Teva Pharmaceutical Industries Ltd
- Mylan N.V.
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Bausch Health Companies Inc.
- H. Lundbeck A/S
- Shionogi & Co Ltd.
- Recordati S.p.A
- Neurocrine Biosciences Inc
- Neuraxpharm
- Actavis Plc.
- Noven Pharmaceuticals Inc.
- Sumitomo Pharma Co. Ltd
- VistaGen Therapeutics
- Valeant Pharmaceuticals International Inc.
- LIFECARE NEURO PRODUCTS LTD.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 11.19 Billion |
Forecasted Market Value ( USD | $ 13.96 Billion |
Compound Annual Growth Rate | 5.7% |
Regions Covered | Global |
No. of Companies Mentioned | 26 |